Phase I Safety Study of Anti-HIV Immune Serum Globulin (Human)

Phase 1

Completed

• Conditions: HIV Infections

• Registration Number: NCT00002036
• Lead Sponsor: Abbott

Brief Summary

To investigate the potential benefit of providing passive immunity with hyperimmune anti-HIV human serum.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 1999-11-02
• Study First Submitted QC: 2001-08-30
• Study First Posted: 2001-08-31
• Status Verified: 2009-02
• Last Update Submitted: 2009-02-19
• Last Update Posted: 2009-02-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Univ of Minnesota; 🇺🇸 Minneapolis, Minnesota, United States